Literature DB >> 15583914

Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.

G M Knudsen1, M Karlsborg, G Thomsen, K Krabbe, L Regeur, T Nygaard, C Videbaek, L Werdelin.   

Abstract

PURPOSE: The aim of this study was to ascertain whether combined presynaptic and postsynaptic dopaminergic single-photon emission computed tomography (SPECT) scanning is useful for differentiation between patients with idiopathic Parkinson's disease (IPD), patients with multiple system atrophy of the striatonigral type (MSA) and healthy subjects.
METHODS: SPECT measurements of the dopamine transporter (DAT) were done with 123I-beta-CIT, while for determination of the dopamine D2-like receptors (D2), 123I-epidepride was used. Clinical evaluation and SPECT scans were carried out in 14 patients with IPD, eight patients with MSA and 11 healthy age-matched control subjects.
RESULTS: Putaminal DAT binding was reduced to 32% of control values in IPD and to 19% of control values in MSA . Significantly higher striatal asymmetry in DAT binding was found in MSA than in controls, but IPD patients had significantly higher asymmetry than MSA patients. Striatal D2 binding did not differ significantly between patients and healthy controls but the ratio between caudate DAT and D2 binding was significantly higher in patients with IPD than in those with MSA, even when disease severity was taken into account.
CONCLUSION: Patients with reduced striatal 123I-beta-CIT binding and a side-to-side difference greater than 15% are likely to suffer from IPD. Patients with reduced striatal 123I-beta-CIT binding and a side-to-side difference of between 5% and 15% are more likely to have MSA. 123I-epidepride SPECT measurements may add further diagnostic information, since the ratio between DAT and D2 receptor binding is significantly higher in IPD than in MSA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583914     DOI: 10.1007/s00259-004-1578-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  20 in total

1.  Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion.

Authors:  L H Pinborg; C Videbaek; G M Knudsen; C G Swahn; C Halldin; L Friberg; O B Paulson; N A Lassen
Journal:  Synapse       Date:  2000-06-15       Impact factor: 2.562

2.  [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Authors:  K Marek; R Innis; C van Dyck; B Fussell; M Early; S Eberly; D Oakes; J Seibyl
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

3.  Effects of age on tissues and regions of the cerebrum and cerebellum.

Authors:  T L Jernigan; S L Archibald; C Fennema-Notestine; A C Gamst; J C Stout; J Bonner; J R Hesselink
Journal:  Neurobiol Aging       Date:  2001 Jul-Aug       Impact factor: 4.673

4.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.

Authors:  D J Brooks; V Ibanez; G V Sawle; E D Playford; N Quinn; C J Mathias; A J Lees; C D Marsden; R Bannister; R S Frackowiak
Journal:  Ann Neurol       Date:  1992-02       Impact factor: 10.422

5.  Differentiation of atypical parkinsonian syndromes with routine MRI.

Authors:  A Schrag; C D Good; K Miszkiel; H R Morris; C J Mathias; A J Lees; N P Quinn
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

6.  Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Authors:  R B Innis; K L Marek; K Sheff; S Zoghbi; J Castronuovo; A Feigin; J P Seibyl
Journal:  Mov Disord       Date:  1999-05       Impact factor: 10.338

7.  Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD.

Authors:  F Yekhlef; G Ballan; F Macia; O Delmer; C Sourgen; F Tison
Journal:  J Neural Transm (Vienna)       Date:  2003-02       Impact factor: 3.575

8.  Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.

Authors:  Yun J Kim; Masanori Ichise; James R Ballinger; Douglas Vines; Sean S Erami; Tatsuro Tatschida; Anthony E Lang
Journal:  Mov Disord       Date:  2002-03       Impact factor: 10.338

9.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.

Authors:  T Brücke; S Asenbaum; W Pirker; S Djamshidian; S Wenger; C Wöber; C Müller; I Podreka
Journal:  J Neural Transm Suppl       Date:  1997

10.  Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging.

Authors:  M Ghaemi; R Hilker; J Rudolf; J Sobesky; W-D Heiss
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

View more
  22 in total

Review 1.  Brain SPECT imaging in multiple system atrophy.

Authors:  R Cilia; G Marotta; R Benti; G Pezzoli; A Antonini
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

Review 2.  Neuroimaging and transcranial ultrasonography in Parkinson's disease.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

3.  EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Authors:  Koen Van Laere; Andrea Varrone; Jan Booij; Thierry Vander Borght; Flavio Nobili; Ozlem L Kapucu; Zuzana Walker; Kjell Någren; Klaus Tatsch; Jacques Darcourt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

4.  Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT.

Authors:  Morten Ziebell; Gerda Thomsen; Gitte M Knudsen; Robin de Nijs; Claus Svarer; Aase Wagner; Lars H Pinborg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 9.236

Review 5.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

6.  Alteration of the regional cerebral glucose metabolism in healthy subjects by glucose loading.

Authors:  Kenji Ishibashi; Kei Wagatsuma; Kiichi Ishiwata; Kenji Ishii
Journal:  Hum Brain Mapp       Date:  2016-04-08       Impact factor: 5.038

7.  Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT.

Authors:  Michael Nocker; Klaus Seppi; Eveline Donnemiller; Irene Virgolini; Gregor K Wenning; Werner Poewe; Christoph Scherfler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-30       Impact factor: 9.236

8.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 9.  Recent developments in multiple system atrophy.

Authors:  Gregor K Wenning; Nadia Stefanova
Journal:  J Neurol       Date:  2009-05-27       Impact factor: 4.849

10.  Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Authors:  S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.